PMID: 18210885Jan 24, 2008Paper

Transhepatic arterial chemoembolization by epirubicin mixed with microspheres for hepatocellular carcinoma

Zhonghua zhong liu za zhi [Chinese journal of oncology]
Jian-jun LuoYi Chen

Abstract

To investigate the safety and efficacy of transhepatic arterial infusion of the mixture of epirubicin and microspheres as the embolization materials for treatment of patients with hepatocellular carcinoma (HCC). The mixture was made of 10-60 mg epirubicin (Pfizer) mixed with 300-500 microm microspheres in 0.5-2 ml (Contour SE Boston Scientific), which was used for embolizating the artery supplying HCC. Changes of leucocyte counts, liver function, serum AFP level, response of tumor to TACE and complications related to embolization were analyzed before and after TACE. 136 HCC patients (male/female: 91/45, mean age: 54.8 +/- 13.3 years) were studied. After TACE, the liver function was damaged and tumor size shrunken significantly (P < 0.05). Transhepatic arterial chemoembolization using the mixture of epirubicin and microspheres for embolizating is safe and effective for the treatment of HCC, but the amount of embolization material should be chosen carefully in order to avoid liver function failure.

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.